x

¿Aún no está registrado?

Cree su cuenta. Regístrese en Elsevier y obtendrá: información relevante, máxima actualización y promociones exclusivas.

Registrarme ahora
Ayuda - - Regístrese - Teléfono 902 888 740
Buscar en

FI 2015

1,530
© Thomson Reuters, Journal Citation Reports, 2015

Indexada en:

Index Current Contents/Clinical Medicine, JCR, SCI-Expanded, Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME, CANCERLIT, SCOPUS

Métricas

  • Factor de Impacto: 1,530(2015)
  • 5-años Factor de Impacto: 1,710
  • SCImago Journal Rank (SJR):0,43
  • Source Normalized Impact per Paper (SNIP):0,653
doi: 10.1016/S0213-005X(04)73107-9
Actualización en la vacunación del adulto
Adult vaccination update
José Luis Arribas1, , María Jesús Hernández-Navarrete, Víctor Manuel Solano
Servicio de Medicina Preventiva. Hospital Universitario Miguel Servet. Zaragoza. España
Recibido 01 marzo 2004, Aceptado 24 marzo 2004
Resumen

La vacunación, en su concepto global, es la estrategia más coste-efectiva en la prevención primaria de enfermedades trasmisibles. Una de las mayores dificultades en la población adulta es alcanzar coberturas vacunales semejantes a las de los programas infantiles. Para solucionar dicho déficit, las estrategias desde el nivel de atención primaria son básicas, ya que es el primer nivel de contacto de la población adulta con los programas de salud. Otros niveles, como el terciario, pueden optar a optimizar la cobertura vacunal en grupos específicos de riesgo. La inmunoterapia activa en el adulto se planifica sobre factores de edad y sexo, pero se añaden circunstancias especiales derivadas de situaciones clínicas, terapéuticas, ocupacionales y otras que pueden ampliar el espectro de inmunógenos a administrar a un adulto.

Resumen

Vaccination, as a global concept, is the most cost-effective strategy in primary prevention of comunicable diseases. One of the bigger difficulties in adult population is to reach the same vaccine coverage as in childhood vaccine programs. In order to solve this deficit, strategies stablished in the primary level are basic, due the fact that it’s the first contact of adult population with health programs. Tertiary level could help to optimize vaccine coverage in specific groups. Active immunization in adults is stablished evaluating factors as age and gender, but specific circunstances associated with medical conditions, treatments or occupation could extend vaccine administration in adults.

Palabras clave
Vacunación, Adulto, Promoción de la salud
Key words
Vaccination, Adult, Health promotion
El Texto completo solo esta disponible en PDF
Bibliografía
1.
Guía de vacunación en el adulto. Grupo de trabajo de vacunación en el adulto
2.
Subdirección General de Epidemiología, Promoción y Educación para la Salud. Dirección General de Salud Pública. Ministerio de Sanidad y Consumo. Cobertura vacunal 1996
Boletín Epidemiológico Semanal, 5 (1997), pp. 37-38
3.
I. Pachón,C. Amela,F. De Ory,P. León,M. Alonso
Encuesta Nacional de Seroprevalencia de Enfermedades Inmunoprevenibles. Año 1996
Boletín Epidemiológico Semanal, 6 (1998), pp. 93-100
4.
Calendario de vacunaciones recomendado por el Consejo Interterritorial del Sistema Nacional de Salud. Programa Nacional de Vacunaciones. Centro Nacional de Epidemiología (consultado 03-02-2004). Disponible en: http://www.isciii/publico.
5.
J. Oromí,J. Vaqué
Estrategias vacunales en el hospital
pp. 657-661
6.
J. Vaqué Rafart
Vacunación en el adulto
pp. 101-110
7.
J.L. Arribas Llorente,V.M. Solano Bernad
Programas de vacunación hospitalaria
pp. 97-118
8.
J.M. Bayas,A. Vilella
Vacunación de adultos. Vacunas
Investigación y práctica, 1 (2000), pp. 173-177
9.
E. Peguero Rodríguez,J. Gené Badia
Estrategias para aumentar la cobertura vacunal del adulto en atención primaria
pp. 83-95
10.
Manual de vacunas en Pediatría
Asociación Española de Pediatría, Comité Asesor de Vacunas, (1995)
11.
E.A. Boylard,O.C. Tablan,W.W. Williams,M.L. Pearson,C.N. Shapiro,S.D. Deitchman
and the Hospital Infection Control Practices Advisory Committee. Guideline for infection control in healthcare personnel, 1998
Infect Control, 19 (1998), pp. 407-463
12.
V.M. Solano,M.J. Hernández,J.L. Del Val,D. Sánchez,M. Torrijos,J.L. Arribas
Recomendaciones para el control de la infección en personal sanitario
Medicina Preventiva, 5 (1999), pp. 28-44
13.
Calendario de vacunaciones recomendadas para adultos por grupos de edad y condiciones médicas, Estados Unidos, 2003-2004. Resumen de las recomendaciones publicadas por el Comité Asesor de Prácticas de Inmunización (consultado 03-02-2004). Disponible en: http://www.cdc.gov/nip
14.
M.P. Farjas Abadía,R. Zubizarreta Alberdi,A. Louro González A,B. Suárez Rodríguez
Laboratorios Esteve, (2003)
15.
Centers for Disease Control and Prevention. Prevention and Control of Influenza. Recomendations of the Advisory Committee on Immunization Practices (ACIP
MMWR, 51 (2002), pp. 8
16.
Centers for Disease Control and Prevention. Prevention of pneumococcal disease
MMWR, 46 (1997), pp. 1-24
17.
A.S. Artz,W.B. Ershler,D.L. Longo
Pneumococcal vaccination and revaccination of older adults
Clin Microbiol Rev, 16 (2003), pp. 308-318
18.
C. Cornu,D. Yzèbe,P. Leophonte,J. Gaillat,J.P. Boissel,M. Cucherat
Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials
Vaccine, 19 (2001), pp. 4780-4790
19.
K. Dear,J. Holden,R. Andrews,D. Tatham
Vaccines for preventing pneumococcal infection in adults (Cochrane Review)
20.
L. Salleras,M. Bruguera,J. Vidal
Cambio del patrón epidemiológico de la hepatitis A en España
Med Clin (Barc, 99 (1992), pp. 87-89
21.
J.A. García-Erce,V.M. Solano,J. Ferrer,J.J. Gimeno
Seroprevalencia de hepatitis A en donantes aragoneses
Sangre, 41 (1996), pp. 485-486
22.
Centers for Disease Control and Prevention. General Recommendations on Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP
MMWR, 51 (2002), pp. 18-19
23.
R.L. Brent
Immunization of pregnant women: reproductive, medical and societal risks
Vaccine, 21 (2003), pp. 3413-3421
24.
J.A. Englund
Maternal immunization with inactivated influenza vaccine: rationale and experience
Vaccine, 21 (2003), pp. 3460-3464
25.
K.M. Edwards
Pertussis: an important target for maternal immunization
Vaccine, 21 (2003), pp. 3483-3486
26.
U.S. Public Health Services (USPHS) and Infectious Diseases Society of America (IDSA) Guidelines for the prevention of opportunistic infections in person infected with human immunodeficiency virus
MMWR Recomm Rep, 48 (1999), pp. 1-46
27.
J. Girón,F. Guerrero,M. Rodríguez
Vacunaciones en el enfermo infectado por el virus de la inmunodeficiencia humana
Rev Clin Esp, 11 (2000), pp. 619-621
28.
Navazo JC, Gamarra N, Hermida JM, Martínez R, Regidor T, Rodríguez A,et al. Profilaxis de enfermedades asociadas: Vacunas e infecciones oportunistas. En: Prevención y Asistencia de la Infección por VIH en Atención Primaria. Ed. Secretaría del Plan Nacional sobre el SIDA. MSyC. Madrid, 2001; p. 96-105.
29.
M.J. Faraldo,M. Jato,B. Suárez,Z.E. Delgado,F. Ledesma
VI promoción diploma de Expertos en Vacunas. Vacunación en adultos portadores del virus de la inmunodeficiencia humana (VIH)
Vacunas, 3 (2002), pp. 150-153
30.
C. Pollet,S.M. Paul,R. Morgan
Immunizations in HIV-infected patients
N Engl J Med, 100 (2003), pp. 32-43
31.
Libman H, Tamar Barlam T. Patient Reference Library: VP02 — A Young Man with HIV. The Carl J. Shapiro Institute for Education and Research at Harvard Medical School and Beth Israel Deaconess Medical Center. Disponible en: http://research.bidmc.harvard.edu/VPTutorials/HIV/
32.
M.C. Rousseau,J. Moreau,J. Delmont
Vaccination and HIV: a review of the literature
Vaccine, 18 (1999), pp. 825-831
33.
M. Plana,F. García,T. Gallart,J.M. Miró,J.M. Gatell
Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease. Immunology Study Group of Spanish EARTH-1 Study
Lancet, 352 (1998), pp. 1194-1195
34.
H. Valdez,E. Connick,K.Y. Smith,M.M. Lederman,R.J. Bosch,R.S. Kim
AIDS Clinical Trials Group Protocol 375 Team. Limited immune restoration after 3 years’ suppression of HIV-1 replication in patients with moderately advanced disease
AIDS, 16 (2002), pp. 1859-1866
35.
J.N. Blankson,J.E. Gallant,R.F. Siliciano
Proliferative responses to human immunodeficiency virus type 1 (HIV-1) antigens in HIV-1-infected patients with immune reconstitution
J Infect Dis, 183 (2001), pp. 657-661
36.
Ch.G. Lange,M.M. Lederman,K. Medvik,R. Asaad,M. Wild,R. Kalayjian
Nadir CD4 count may predict immunity: nadir CD4+T-cell count and numbers of CD28+CD4+T-cells predict functional responses to immunizations in chronic HIV-1 infection
AIDS, 17 (2003), pp. 2015-2023
37.
A. Vigano,D. Bricalli,D. Trabattoni,A. Salvaggio,S. Ruzzante,M. Barbi
Immunization with both T cell-dependent and T cell-independent vaccines augments HIV viral load secondarily to stimulation of tumor necrosis factor alpha
AIDS Res Hum Retroviruses, 14 (1998), pp. 727-734
38.
D. Rey,D. Krantz,M. Partisani,M.P. Schmitt,P. Meyer,E. Libbrecht
Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load
Vaccine, 18 (2000), pp. 1161-1165
39.
H.F. Günthard,J.K. Wong,C.A. Spina,C. Ignacio,S. Kwok,C. Christopherson
Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy
J Infect Dis, 181 (2000), pp. 522-531
40.
L.A. Pinto,V. Blazevic,S.A. Anderson,D.J. Venzon,C. Mac Trubey,T. Rowe
Influenza virus-stimulated generation of anti-human immunodeficiency virus (HIV) activity after influenza vaccination in HIV-infected individuals and healthy control subjects
J Infect Dis, 183 (2001), pp. 1000-1008
41.
E. Negredo,P. Domingo,M.A. Sambeat,N. Rabella,G. Vázquez
Effect of pneumococcal vaccine on plasma HIV-1 RNA of stable patients undergoing effective highly active antiretroviral therapy
Eur J Clin Microbiol Infect Dis, 20 (2001), pp. 287-288
42.
M.B. Goetz,D.R. Feikin,J.L. Lennox,W.A. O’Brien,C.M. Elie,J.C. Butler
Viral load response to pneumococcal conjugate vaccine, polysaccharide vaccine or placebo among HIV-infected patients
AIDS, 16 (2002), pp. 1421-1423
43.
A.R. Zanetti,A. Amendola,S. Besana,A. Boschini,E. Tanzi
Safety and immunogenicity of influenza vaccination in individuals infected with HIV
Vaccine, 20 (2002), pp. B29-B32
44.
D.J. Skiest,T. Machala
Comparison of the effects of acute influenza infection and influenza vaccination on HIV viral load and CD4 cell counts
J Clin Virol, 26 (2003), pp. 307-315
45.
CDC. Measles, Mumps, and Rubella vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP
MMWR, 47 (1998), pp. 1-67
46.
CDC. Prevention of varicella. Update recommendations of the Advisory Committee on Immunization Practices (ACIP)
MMWR Recomm Rep, 48 (1999), pp. 1-5
47.
CDC. Smallpox vaccination clinic guide
48.
J.G. Bartlett
Samallpox vaccination and patients with human immunodefiency virus infection or acquired immunodeficiency syndrome
Clin Infect Dis, 36 (2003), pp. 468-471
49.
V.K. Amorosa,S.N. Isaacs
Separate worlds set to collide: smallpox, vaccinia virus vaccination, and human immunodeficiency virus and acquired immunodeficiency syndrome
Clin Infect Dis, 37 (2003), pp. 426-432
50.
D.R. Feikin,C.M. Elie,M.B. Goetz,J.L. Lennox,G.M. Carlone,S. Romero-Steiner
Specificity of the antibody response to the pneumococcal polysaccharide and conjugate vaccines in human immunodeficiency virus-infected adults
Clin Diagn Lab Immunol, 11 (2004), pp. 137-141
51.
M.C. Rodríguez-Barradas,I. Alexandraki,T. Nazir,M. Foltzer,D.M. Musher,S. Brown
Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine
Clin Infect Dis, 37 (2003), pp. 438-447
52.
S.A. Tasker,M.R. Wallance,J.B. Rubins,W.B. Paxton,J. O’Brien,E.N. Janoff
Reimmunization with 23-valent pneumococcal vaccine for patients infected with human immunodeficiency virus type 1: clinical, immunologic, and virologic responses
Clin Infect Dis, 34 (2002), pp. 813-821
53.
M.E. Valencia,J.M. González
¿Cuáles son las vacunas que deben recibir los pacientes infectados del virus de la inmunodeficiencia humana?
An Med Interna, 15 (1998), pp. 439-442
54.
D.H. Dockrell,G.A. Poland,J.M. Steckelberg,P.C. Wollan,S.R. Strickland,C. Pomeroy
Immunogenicity of three Haemophilus influenzae type b protein conjugate vaccines in HIV seropositive adults and analysis of predictors of vaccine response
Vaccine, 17 (1999), pp. 2779-2785
55.
F. Castelli,A. Patroni
The human immunodeficiency virus-infected traveler
Clin Infect Dis, 31 (2000), pp. 1403-1408
56.
D.M. Ambrosino,D.C. Molrine
Critical appraisal of immunization strategies for prevention of infection in the compromised host
Hematol Oncol Clin North Am, 7 (1993), pp. 1027-1050
57.
J.M. Rowe,N. Ciobanu,J. Ascensao,E.A. Stadtmauer,R.S. Weiner,D.P. Schenkein
Recommended guidelines for the management of autologous and allogeneic bone marow transplantation
Ann Intern Med, 120 (1994), pp. 143-158
58.
J. Somani,R.A. Larson
Reimmunization after allogeneic bone marrow transplantation
Am J Med, 98 (1995), pp. 389-398
59.
P. Ljungman,C. Cordonnier,R. De Bock,H. Einsele,D. Engelhard,J. Grundy
Immunisations after bone marrow transplantation: results of a European survey and recommendations from the infectious diseases working party of the European Group for Blood and Marrow Transplantation
Bone Marrow Transplant, 15 (1995), pp. 455-460
60.
R. De la Cámara,C. Bischofberger,M. Campins,E. Carreras
Inmunización postrasplante de progenitores hematopoyéticos: revisión y recomendaciones
Med Clin (Barc, 110 (1998), pp. 146-155
61.
S. Singhal,J. Mehta
Reimmunization after blood or marrow stem cell transplantation
Bone Marrow Transplant, 23 (1999), pp. 637-646
62.
M.K. Gandhi,W. Egner,L. Sizer,I. Inman,M. Zambon,J.I.O. Craig
Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peropheral blood stem cell and bone marrow transplantation recipients
Bone Marrow Transplant, 28 (2001), pp. 775-781
63.
Centers for Disease Control and prevention. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation
MMWR Morb Mortal Wkly Rep, 49 (2000), pp. 1-125
64.
D.C. Molrine,P.L. Hibberd
Vaccines for transplant recipients
Infect Dis Clin North Am, 15 (2001), pp. 273-305
65.
T. Parkkali,M. Stenvik,T. Ruutu,T. Hovi,L. Volin,P. Ruutu
Randomized comparison of early and late vaccination with inactivated poliovirus vaccine after allogeneic BMT
Bone Marrow Transplant, 20 (1997), pp. 663-668
66.
C.Y. Chan,D.C. Molrine,J.H. Antin,C. Wheeler,E.C. Guinan,H.J. Weinstein
Antibody responses to tetanus toxoid and Haemophilus influenzae type b conjugate vaccines following autologous peripheral blood stem cell transplantation (PBSCT
Bone Marrow Transplant, 20 (1997), pp. 33-38
67.
E. Vance,S. George,E.C. Guinan,C. Wheler,J.H. Antin,D.M. Ambrosino
Comparison in the multiple immunization schedules for Haemophilus influenzae type b-conjugate and tetanus toxoid vaccines following bone marrow transplantation
Bone Marrow Transplant, 22 (1998), pp. 735-741
68.
C. Adell,J.M. Bayas,A. Vilella,M. Perales,J. Vidal,M.J. Bertran
Vacunación de pacientes receptores de trasplante de progenitores hematopoyéticos
Med Clin (Barc, 119 (2002), pp. 405-409
69.
L. Méndez,M. Campins,F. Ramos,E. Ferrer
Vacunación frente a la hepatitis B y trasplante de progenitores hematopoyéticos
Med Clin (Barc, 121 (2003), pp. 37-38
70.
J.C. Sanz,R. De la Cámara,C. Bischofberger,J. Casal
Non conjugate pneumococcal vaccine and Haemophilus influenzae type b vaccine in haemopoietic transplantation
Vacunas, 4 (2003), pp. 30-33
71.
L. Volti,L. Mauro,F. Di Gregorio,M.A. Romeo,L. Lupo,G. Pizzarelli
Immune status and immune response to diphtheria-tetanus and polio vaccines in allogeneic bone marrow-trasplanted thalassemic patients
Bone Marrow Transplant, 14 (1994), pp. 225-227
72.
D.C. Molrine,E.C. Guinan,J.H. Antin,S.K. Parson,H.J. Weinstein,C. Wheeler
Donor immunization with Haemophilus influenzae type b (Hib)-conjugate vaccine in allogeneic bone marrow transplantation
Blood, 87 (1996), pp. 3012-3018
73.
E.C. Guinan,D.C. Molrine,J.H. Antin,M.C. Lee,H.J. Weinstein,S.E. Sallan
Polysaccharide conjugate vaccine responses in bone marrow transplantation patients
Transplantation, 57 (1994), pp. 677-684
74.
D.C. Molrine,J.H. Antin,E.C. Guinan,R.J. Soiffer,K. MacDonald,R. Malley
Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell trasplantation
Blood, 101 (2003), pp. 831-836
75.
T. Parkkali,H. Kayhty,H. Lethonen,T. Ruutu,L. Volin,J. Eskola
Tetravalent meningococcal polysaccharide vaccine is immunogenic in adult allogeneic BMT recipients
Bone Marrow Transplant, 27 (2001), pp. 79-84
76.
E.J.A. Itsen,M.J.D. Van Tol,M.B. Van’t Veer,J.M.A. Wels,I.M.S.L. Khouw,C.R. Touw
Clonal dysregulation of the antibody response to tetanus-toxoid after bone marrow trasplantation
Blood, 84 (1994), pp. 4374-4382
77.
S.A. Brugger,C. Oesterreicher,H. Hofmann,P. Kalhs,H.T. Greinix,C. Muller
Hepatitis B virus clearance by trasplantation of bone marrow trasplantation from hepatitis B immunised donor
Lancet, 349 (1997), pp. 996-997
78.
M. Vavassori,R. Maccario,A. Moretta,P. Comoli,A. Wack,F. Locatelli
Restricted TCR repertoire and long-term persistence of donor-derived antigen + experienced CD4 + T cells in allogeneic bone marrow trasplantation recipients
J Immunol, 157 (1996), pp. 5739-5747
79.
A. Hata,H. Asanuma,M. Rinki,M. Sharp,R.M. Wong,K. Blume
Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplantation
N Engl J Med, 347 (2002), pp. 26-34
80.
R. Patel,C.V. Paya
Infections in solid-organ transplant recipients
Clin Microbiol Review, 10 (1997), pp. 86-124
81.
J. Ayats-Ardite,J.M. Cisneros-Herreros,J.L. Pérez-Saenz,J. De la Torre-Cisneros
Evaluación de las enfermedades infecciosas en el candidato a un trasplante de órgano sólido
Enferm Infecc Microbiol Clin, 20 (2002), pp. 448-461
82.
R.K. Avery
Immunizations in adult immunocompromised patients: which to use and which to avoid
Cleveland Clin J M, 68 (2001), pp. 337-348
83.
J.A. Kobashigawa,L. Warner-Stevenson,B.L. Johnson,J.D. Moriguchi,N. Kawata,D.C. Drinkwater
Influenza vaccine does not cause rejection after cardiac transplantation
Transplant Proc, 25 (1993), pp. 2738-2739
84.
E.A. Blumberg,J. Fitzpatrick,P.C. Stutman,F.G. Hayden,S.C. Brozena
Safety of influenza vaccine in heart transplant recipients
J Heart Lung Transplant, 17 (1998), pp. 1075-1080
85.
P. Kimbal,S. Verbeke,M. Flattery,C. Rhodes,D. Tolman
Influenza vaccination does not promote cellular and humoral activation among transplant recipients
Transplantation, 69 (2000), pp. 2449-2451
86.
A. Duchini,J.A. Goss,S. Karpen,P.J. Pockros
Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols
Clin Microbiol Review, 16 (2003), pp. 357-364
87.
M. Burroughs,A. Moscona
Immunization of pediatric solid-organ transplant candidates and recipients
Clin Infect Dis, 30 (2000), pp. 857-869
88.
L.K. Dropulic,R.H. Rubin,J.G. Bartlett
Smallpox vaccination and the patient with an organ transplant
Clin Infect Dis, 36 (2003), pp. 786-788
89.
K.A. Sepkowitz
How contagious is vaccinia
N Engl J Med, 348 (2003), pp. 439-446
90.
T.J. Dengler,N. Strnad,I. Buhring,R. Zimmermann,O. Girgsdies,W.E. Kubler
Differential immune response to influenza and pneumococcal vaccination in immunosuppressed patients after heart trasplantation
Trasplantation, 66 (1998), pp. 1340-1347
91.
A. Duchini,R.M. Hendry,L.M. Nyberg,M.E. Viernes,P.J. Pockros
Immune response to influenza vaccine in adult liver transplant recipients
Liver Transpl, 7 (2001), pp. 311-313
92.
M.S. Sever,A. Yildiz,H. Eraksoy,S. Badur,D. Yuksel-Onel,B. Gorcin
Immune response to Haemophilus influenzae type b vaccination in renal transplant recipients with well-functionating allografts
Nephron, 81 (1999), pp. 55-59
93.
E.B. Keeffe
Is hepatitis A more severe in patients with chronic hepatiris B and other chronic liver diseases?
Am J Gastroenterol, 90 (1995), pp. 201-205
94.
S. Vento,T. Garofano,C. Renzini,F. Cainelli,F. Casali,G. Ghironzi
Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C
N Engl J Med, 338 (1998), pp. 286-290
95.
K. Stark,M. Günther,R. Neuhaus,P. Reinke,K. Schr¿der,S. Linning
Immunogenicity and safety of hepatitis A vaccine in liver and renal transplant recipients
J Infect Dis, 180 (1999), pp. 2014-2017
96.
A. Sánchez-Fueyo,A. Rimola,L. Grande,J. Costa,A. Mas,M. Navasa
Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation
Hepatology, 31 (2000), pp. 496-501
97.
P.I. Hibberd,R.H. Rubin
Approach to immunization in the immunosuppressed host
Infect Dis North Am, 4 (1990), pp. 123-142
98.
R.K. Zimmerman,E.R. Ahwesh
Adult vaccination, part 2: vaccines for persons at high risk. Teaching immunization for Medical Education (TIME) Project
J Fam Pract, 49 (2000), pp. 51-63
99.
R.K. Zimmerman,D.B. Middleton,N.J. Smith
Vaccines for persons at high risk due to medical conditions, occupation, environment, or lifestyle 2003
J Fam Pract, 52 (2003), pp. 22-23
100.
R.N. Davidson,R.A. Wall
Prevention and management of infections in patients without a spleen
Clin Microbiol Infect, 7 (2001), pp. 657-660
101.
R. Cohen
Antipneumococcal vaccines in sickle-cell anemia and asplenia
Presse Med, 32 (2003), pp. 12-14
102.
R. Pérez Maestu,R.M. Daza Pérez,L. Álvarez Ayuso
Estudio comparativo del papel protector de la vacuna frente a Haemophilus influenzae tipo b y de la esplenectomía parcial en un modelo experimental
Enferm Infecc Microbiol Clin, 15 (1997), pp. 5-9
103.
P. Balmer,M. Falconer,P. McDonald,N. Andrews,E. Fuller,C. Riley
Immune response to meningococcal serogroup C conjugate vaccine in asplenic indiviuals
Infect Immun, 72 (2004), pp. 332-337
104.
M. Sans,S. Escorza,D. Villagrasa,E. Comin,A. Ezpeleta,C. Batalla
Portadores de hepatitis C: ¿Tenemos que vacunarlos a todos de la hepatitis A?
Aten Primaria, 30 (2002), pp. 80-84
105.
A. Pareja
Portadores de la hepatitis C. ¿hay que vacunarlos a todos frente a la hepatitis A?
Aten Primaria, 30 (2002), pp. 84-85
106.
M. Makris,C.P. Conlon,H.G. Watson
Immunization of patients with bleeding disorders
Haemophilia, 9 (2003), pp. 541-546
107.
Centers for Disease Control and Prevention (CDC). Recommendations for Preventing Transmission of Infections among Chronic Hemodialysis Patients
MMWR, 50 (2001), pp. 1-63
108.
M.C. Rangel,V.G. Coronado,G.L. Euler,R.A. Strikas
Vaccine recommendations for patients on chronic dialysis. The Advisory Committee on Immunizations practices and the American Academy of Pediatrics
Sem Dial, 13 (2000), pp. 101-107
109.
M. Jadoul,P. Goubau
Is anti-hepatitis B virus (HBV) immunization successful in ederly hemodialysis (HD) patients?
Clin Nephrol, 58 (2002), pp. 301-304
110.
V. Kovacic,M. Sain,V. Vukman
Efficient haemodialysis improves the response to hepatirtis B virus vaccination
Intervirology, 45 (2002), pp. 172-176
111.
K. Hassan,L. Shternberg,M. Alhaj,R. Giron,R. Reshef,M. Barak
The effect of erythropoietin therapy and hemoglobin levels on the immune response to Engerix-B vaccination in chronic kidney disease
Ren Fail, 25 (2003), pp. 471-478
112.
K.S. Eardley,H.E. Jones,H. Osman,S.A. Smith
Efficacy of the accelerated hepatitis B vaccination schedule used in haemodialysis patients pst-exposure to virus: a single-centre experience
Nephrol Dial Transplant, 17 (2002), pp. 1982-1987
113.
S. Saab,S.R. Weston,D. Ly,M. Brezina,H.F. Yee,S.H. Han
Comparison of the cost and effectiveness of two strategies for maintaining hepatitis B immunity in hemodialysis patients
Vaccine, 20 (2002), pp. 3230-3235
114.
G.M. Keating,S. Noble
Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hetatitis B
Drugs, 63 (2003), pp. 1021-1051
115.
S. Kruger,M. Seyfarth,K. Sack,B. Kreft
Defective immune response to tetanus toxoid in hemodialysis patients and its association with diphteria vaccination
Vaccine, 17 (1999), pp. 1145-1150
116.
E. Sonmez,A.S. Sonmez,Y. Bayindir,D. Coskun,S. Ariturk
Antihepatitis B response to hepatitis B vaccine admistered simultaneosly with tetanus toxoid in nonresponder individuals
Vaccine, 21 (2002), pp. 243-246
117.
Advisory Committee Statement & National Advisory Committee on Immunization. Update to statement on varicella vaccine
Can Comm D R (CCDR), 28 (2002), pp. 1-8
118.
E.H. Fleischmann,J. Kruppenbacher,H.L. Bock,M. Weber
Active immunization against hepatitis A in dialysis patients
Nephrol Dial Transplant, 17 (2002), pp. 1825-1828
119.
Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee (HICPAC). Immunization of health-care workers
MMWR, 46 (1997), pp. 1-51
120.
Are booster immunizations needed for lifelong hepatitis B immunity? European Consensus group on Hepatitis B Immunity
Lancet, 355 (2000), pp. 561-565
121.
A. Floreani,V. Baldo,M. Cristofoletti,G. Renzulli,A. Valeri,C. Zanetti
Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers
Vaccine, 22 (2004), pp. 608-611
122.
J.R. Pallás Álvarez,M.S. Gómez Holgado,J. Llorca Díaz,M. Delgado Rodríguez
Vacunación de la hepatitis B. Indicaciones del test serológico postvacunal y la dosis de refuerzo
Rev Esp Salud Publica, 74 (2000), pp. 475-482
123.
De Juanes JR, Arrazola MP. Vacunación en sanitarios. Cp. XI en: Vacunaciones en el Adulto. Guía y Recomendaciones
124.
Centers for Disease Control and prevention. Prevention and Control of Infections with hepatitis viruses in correctional settings
MMWR, 52 (2003), pp. 1-44
125.
Adult Immunizations. Massachussetts Recommendations and Requeriments for 2003. Disponible en: www.state.ma.us/dph/cdc/epii/imm/adult/adultguidelinesHA2003.pdf
126.
Occupational health and safety program for perssonnel with animal contact. WashingtonUniversity. 1997. Disponible en: dcmin/o.wustl.edu/occhealth/occuhealth_program.pdf
127.
Departamento de Salud y Consumo. Diputación General de Aragón. Guía de Inmigración y salud. (consultado en 12-02-04). Disponible en: http://www.aragob.es
128.
Generalitat Valenciana. Conselleria de Sanitat. Guía de vacunaciones para inmigrantes
129.
Ministerio de Sanidad y Consumo. La salud también viaja, consejos y normas sanitarias para viajeros internacionales
Correspondencia: Dr. J.L. Arribas. Servicio de Medicina Preventiva. Hospital Universitario Miguel Servet. P.° Isabel la Católica, 1-3. 50009 Zaragoza. España.
Copyright © 2004. Elsevier España, S.L.